New drug shows promise in fighting rare eye cancer
NCT ID NCT06717126
First seen Jan 17, 2026 · Last updated May 23, 2026 · Updated 17 times
Summary
This study tests a new drug called roginolisib in adults with advanced uveal melanoma, a rare eye cancer that has spread. About 85 participants will receive either roginolisib or standard treatment to see if the drug helps them live longer and improves their quality of life. The goal is to find a better option for people whose cancer has worsened after initial immunotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UVEAL MELANOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
A.O.U.S. Santa Maria delle Scotte
Siena, 53100, Italy
-
Beatson West of Scotland Cancer Centre, Glasgow (NHS Greater Glasgow & Clyde)
Glasgow, G12 0YN, United Kingdom
-
Complejo Hospitalario Universitario de Santiago - CHUS
Santiago de Compostela, 15706, Spain
-
Consorcio Hospital General Universitario de València - CHGUV
Valencia, 46014, Spain
-
East and North Hertfordshire NHS Trust (Mount Vernon Cancer Centre)
Northwood, Middlesex, HA6 2RN, United Kingdom
-
Hospital Universitario La Paz
Madrid, 28046, Spain
-
Hospital Universitario Virgen Macarena, University of Seville
Seville, Spain
-
IRCCS Istituto Clinico Humanitas
Rozzano, 20089, Italy
-
IRCSS Istituto Oncologico Veneto UOS Oncologia 2 del Melanoma Ospedale Busonera
Padova, 35128, Italy
-
IRCSS National Cancer Institute, "G.Pascale" Foundation Dip. CORP-S di Ricerca ed Assistenziale Cute, Melanoma lmmunologia Oncologica Sperimentale e Terapie Innovative
Naples, 80131, Italy
-
Institut Catala d'Oncologia - ICO L'Hospitalet
Barcelona, 08908, Spain
-
Royal Marsden Hospital
London, SW3 6JJ, United Kingdom
-
SSD Tumori Rari e Melanoma Viale Orazio Flacco
Bari, 70124, Italy
-
The Clatterbridge Cancer Centre NHS Foundation Trust
Bebington, Wirral, CH63 4JH, United Kingdom
-
University College London Hospital NHS
London, NW1 2PG, United Kingdom
-
University Hospital Southampton NHS Foundation
Southampton, SO16 6YD, United Kingdom
Conditions
Explore the condition pages connected to this study.